Literature DB >> 11881891

Concurrent ketamine and alfentanil administration: pharmacokinetic considerations.

S R Edwards1, C F Minto, L E Mather.   

Abstract

BACKGROUND: A ketamine-alfentanil combination has been suggested for total i.v. anaesthesia. We determined the pharmacokinetics of ketamine and alfentanil, alone and together, in three groups of adult male rats, to assess any pharmacokinetic interaction.
METHODS: Group 1 animals were infused with i.v. ketamine for 5 min; in group 2, constant low plasma concentrations of alfentanil were maintained by computer-controlled infusion; in group 3, the treatments were combined. Serial plasma and terminal tissue concentrations were measured by high performance liquid chromatography or gas chromatography-mass spectrometry.
RESULTS: In the presence of alfentanil, the mean plasma ketamine concentration-time area under the curve (AUC) value was significantly lower (by 13%, P<0.05), while clearance (CIT) and volume of distribution (Vss) were significantly higher (by 16 and 28%, respectively, both P<0.05). Tissue:plasma distribution coefficients for ketamine in the presence of alfentanil were significantly higher in forebrain (by 128%, P<0.005), hindbrain (by 207%, P<0.01), gut (by 254%, P<0.005), and fat (by 344%, P<0.0001). Mean AUC values for alfentanil did not differ significantly in the presence of ketamine, but alfentanil tissue concentrations were significantly lower in forebrain (by 77%, P<0.0001), hindbrain (by 28%, P<0.01), heart (by 33%, P<0.01), lung (30%, P<0.05), and gut (by 21%, P<0.05). Corresponding tissue:plasma distribution coefficients were significantly lower for forebrain (by 69%, P<0.0001) alone.
CONCLUSIONS: The finding that the distribution of ketamine into the brain was increased by low plasma concentrations of alfentanil could have important clinical applications for pain management.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11881891     DOI: 10.1093/bja/88.1.94

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  7 in total

1.  NMDA receptor antagonists distort visual grouping in rats performing a modified two-choice visual discrimination task.

Authors:  Katja Clarissa Ward; Halima Zainab Khattak; Louise Richardson; Jonathan Loon Choon Lee; Martin Vreugdenhil
Journal:  Psychopharmacology (Berl)       Date:  2013-05-07       Impact factor: 4.530

Review 2.  Ketamine as an adjuvant to opioids for cancer pain.

Authors:  Rae F Bell; Christopher Eccleston; Eija A Kalso
Journal:  Cochrane Database Syst Rev       Date:  2017-06-28

3.  Neonatal PCP is more potent than ketamine at modifying preweaning behaviors of Sprague-Dawley rats.

Authors:  Sherin Y Boctor; Cheng Wang; Sherry A Ferguson
Journal:  Toxicol Sci       Date:  2008-07-30       Impact factor: 4.849

4.  An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder.

Authors:  Leorey N Saligan; David A Luckenbaugh; Elizabeth E Slonena; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  J Affect Disord       Date:  2016-01-19       Impact factor: 4.839

5.  Nanostructure initiator mass spectrometry: tissue imaging and direct biofluid analysis.

Authors:  Oscar Yanes; Hin-Koon Woo; Trent R Northen; Stacey R Oppenheimer; Leah Shriver; Jon Apon; Mayra N Estrada; Michael J Potchoiba; Rick Steenwyk; Marianne Manchester; Gary Siuzdak
Journal:  Anal Chem       Date:  2009-04-15       Impact factor: 6.986

6.  Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat.

Authors:  T O Lilius; V Jokinen; M S Neuvonen; M Niemi; E A Kalso; P V Rauhala
Journal:  Br J Pharmacol       Date:  2015-06       Impact factor: 8.739

7.  Physiologically based pharmacokinetic modeling of arterial - antecubital vein concentration difference.

Authors:  David G Levitt
Journal:  BMC Clin Pharmacol       Date:  2004-02-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.